

NOUS TRACTAMENTS BIOLÒGICS EN L'ASMA BRONQUIAL

XXXI DIADA PNEUMOLÒGICA, Sitges 12 d'Abril de 2013



Dr. Christian Domingo Ribas
(cdomingo@tauli.cat)

Professor Associat
Departament de Medicina
Universitat Autònoma de Barcelona

Consultor del Servei de Pneumologia
Corporació Sanitària i Universitària Parc Taulí
Sabadell


MECANISMES D'ACTUACIÓ (I)- ANTICOSSOS MONOCLONALS

Ac Anti-IgE




MECANISMES D'ACTUACIÓ (II)-ANTICOSSOS MONOCLONALS

Ac Anti-IL




Anti-ILR




Antagonisme competitiu

MECANISMES D'ACTUACIÓ (III)- “Anti-sense Therapy”


DEFINICIÓ: Se'n diu teràpia anti-sentit per que són un conjunt d'oligonucleòtids que tenen una seqüència de bases complementària a la del mRNA que codifica una proteïna.



MECANISMES D'ACTUACIÓ (III) - “Anti-sense Therapy”




FISIOPATOLOGIA DE LA REACCIÓ AL·LÈRGICA




FISIOPATOLOGIA DE LA REACCIÓ AL·LÈRGICA

a) Sensibilització



b) Fase immediata: Reacció tipus 1




Degranulació:


LLiberació d'histamina,
prostaglandines, leucotriens...

FISIOPATOLOGIA DE LA REACCIÓ AL·LÈRGICA

c) Fase tardana: inflamació al·lèrgica




FISIOPATOLOGIA DE LA REACCIÓ AL·LÈRGICA




TRACTAMENTS ANTI-IgE

- Bloquejants de la IgE: **Omalizumab, Ligelizumab.**
- Bloquejants de la producció d'IgE: **Quilizumab**
- Bloquejant del receptor per la IgE de baixa afinitat FcεRII: **Lumiliximab**

FISIOPATOLOGIA DE LA REACCIÓ AL·LÈRGICA




- The Cε3 domain is the portion of the IgE molecule that binds to the membrane receptors.
- The key epitope is the Cε3 domain of human IgE






FISIOPATOLOGIA DE LA REACCIÓ AL·LÈRGICA

Allergen and mast cell



FISIOPATOLOGIA DE LA REACCIÓ AL·LÈRGICA



Original article

Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients

Christian Domingo
Amalia Moreno

Pneumology Service, Corporació Parc Taulí, Sabadell, Spain
Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

M^a José Amengual

Laboratory Service, Immunology Section, UDIAT, Corporació Parc Taulí, Sabadell, Spain

Concepción Montón

Pneumology Service, Corporació Parc Taulí, Sabadell, Spain

David Suárez

Epidemiology and Assessment Unit, Parc Taulí Foundation, Universitat Autònoma de Barcelona (UAB), Sabadell, Spain

Xavier Pomares,

Pneumology Service, Corporació Parc Taulí, Sabadell, Spain
Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

Address for correspondence: Christian Domingo, MD, Pulmonary Service, Hospital de Sabadell (Corporació Parc Taulí), Parc Taulí s/n, 08208 Sabadell, Barcelona, Spain.
Tel.: +34-93-723 10 10 ext 29 142; Fax: +34-93 716 06 46; cdomingo@tauli.cat

Key words:

Asthma – Oral corticosteroids – Omalizumab – Drug tolerance

Abstract

Background:

Several studies have demonstrated the beneficial effects of omalizumab in asthma patients. Here we describe the drug's tolerance and oral corticosteroid sparing capacity in a long-term observational study.

Methods:

Thirty-two patients aged ≥ 18 years with obstructive airway disease and FEV₁ reversibility $\geq 12\%$ and 200 mL, with an oral steroid requirement ≥ 7.5 mg per day of prednisolone during a period of ≥ 1 year, a positive prick test or in vitro reactivity (RAST) to at least one perennial aeroallergen and a baseline immunoglobulin E level ranking between 30–700 IU/mL were prospectively followed for 17.2 $\pm$ 8.5 months. Patients were visited once or twice a month, depending on their schedule for omalizumab administration. Intervention: blood analysis every six months; spirometry and nitric oxide measurement at every visit.

Results:

One patient who dropped out early was excluded. Follow-up period: the treatment benefited 83.9% (26/31) of the cohort; oral corticosteroids were reduced from 7.19 $\pm$ 11.1 to 3.29 $\pm$ 11.03 mg ($p < 0.002$) and withdrawn in 74.2% of patients. FEV₁ (percent predicted) was 64.4 $\pm$ 22.7 at the beginning and 62.9 $\pm$ 24.3 at the end. IgE at entry was 322.2 $\pm$ 334.2 IU/mL and increased 2.34-fold. Respiratory function and NO did not present statistically significant changes. We identified three groups of patients: the first ($n = 17$) receiving oral steroid at entry in whom the accumulated dose of oral steroids progressively decreased; another ($n = 10$) including patients who had quit oral steroids before starting omalizumab although they had not been instructed to do so and whose oral steroid dose at the end of follow-up was zero; and a third group ($n = 4$) that did not benefit from omalizumab treatment. The only relevant side effect was a flu-like syndrome which required discontinuation of treatment in one patient.

Conclusion:

In our series, a substantial, safe decrease in oral corticosteroid requirements was observed due, at least to some extent, to omalizumab therapy. Oral corticosteroids were withdrawn in three-quarters of the patients. We were unable to identify a factor able to predict which patients would benefit most from omalizumab treatment.

Original article


Omalizumab in the management of oral
corticosteroid-dependent IGE-mediated
asthma patients

Figure 1. (A) Overall view of initial and end oral corticosteroid intake. (B) Exhaled NO. (C) IgE concentrations. Note the significant decrease of oral corticosteroid intake whilst the exhaled NO remains stable. As a result of the omalizumab treatment, IgE levels notably increased.

Original article


Omalizumab in the management of oral
corticosteroid-dependent IGE-mediated
asthma patients

Figure 2. The spirometry results of the cohort of patients are given as a percentage of the predicted results. Note that the FEV₁ values (C) do not fall despite the decrease of oral corticosteroids, whilst the FVC (B) and FEV₁/FVC (A) do not change, ensuring that the airway obstruction does not progress and that there is no subsequent increase in the residual volume.

Original article


Omalizumab in the management of oral
corticosteroid-dependent IGE-mediated
asthma patients

Figure 3. Note the monthly progressive decrease of the accumulated oral corticosteroid dose.

Original article

Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients






Figure 5. This group is the smallest cohort of patients who did not respond to omalizumab treatment. Their corticosteroid intake was erratic and could not be related to any specific factor.

Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry


LUIS PÉREZ DE LLANO, M.D., PH.D.,¹ MARÍA DEL CARMEN VENNERRA, M.D.,^{2,3,4} FRANCISCO J ÁLVAREZ, M.D.,⁵
 JUAN F. MEDINA, M.D.,⁵ LUIS BORDERÍAS, M.D., PH.D.,⁶ CONCHA PELLICER, M.D.,⁷
 HÉCTOR GONZÁLEZ, M.D., PH.D.,⁸ JOSÉ A. GULLÓN, M.D., PH.D.,⁸ EVA MARTÍNEZ-MORAGÓN, M.D., PH.D.,⁹
 CARLOS SABADELL, M.D.,¹⁰ SOLEDAD ZAMARRO, M.D.,¹¹ AND CÉSAR PICADO, M.D., PH.D.,^{2,3,4}; on behalf of
 the Spanish Registry




** Statistically significant differences were observed regarding baselining visit (Wilcoxon test; $p < .05$)



** Statistically significant differences were observed regarding baselining visit (Wilcoxon test; $p < .05$)



** Statistically significant differences were observed regarding baselining visit (Wilcoxon test; $p < .05$)



** Statistically significant differences were observed regarding baselining visit (Wilcoxon test; $p < .05$)

EFFECTIVENESS OF OMALIZUMAB IN NON-ALLERGIC SEVERE ASTHMA

C. DOMINGO^{1,2}, X. POMARES^{1,2}, N. ANGRILL^{1,2}, N. RUDF³, M.J. AMENGUAL^{2,4}
and R.M. MIRAPEIX⁵




Figure 1




Figure 2






Figure 3


When and how omalizumab can be withdrawn: free IgE as a possible biomonitor.



When and how omalizumab can be withdrawn: free IgE as a possible biomonitor.



When and how omalizumab can be withdrawn: free IgE as a possible biomonitor.



Monitoring free serum IgE in severe asthma patients treated with omalizumab

Stephanie Korn^{a,*}, Ina Haasler^a, Florian Fliedner^a, Gunther Becher^b, Pavel Strohner^c, Antonia Staatz^c, Christian Taube^a, Roland Buhl^a

^a Pulmonary Department, Mainz University Hospital, Langenbeckstrasse 1, D-55131 Mainz, Germany

^b BecherConsult GmbH, 16321 Bernau, Germany

^c BioTeZ Berlin-Buch GmbH, 13125 Berlin, Germany

Received 15 May 2012; accepted 23 July 2012

Respiratory Medicine (2012)



[AQ1]

Can Omalizumab Be Effective in Chronic Eosinophilic Pneumonia?

To the Editor:

We have recently read with interest the article by Kaya et al¹ in *CHEST* (August 2012) reporting on a patient suffering from chronic eosinophilic pneumonia (CEP) who responded successfully to omalizumab.

Five years ago, we attended a 43-year-old nonsmoking man who complained of cough, fever, dyspnea, and wheezing. On the basis of his clinical presentation, peripheral blood and BAL eosinophilia, and the presence of bilateral peripheral infiltrates on the chest radiograph, the diagnosis of CEP was made. As in the Kaya et al¹ case, oral corticosteroids (OCs) were started with an initial successful response. After 3 months of therapy, the dose of OC was progressively tapered. When the dose reached 10 mg prednisolone, a relapse occurred that forced us to increase the dose of OC. The patient improved and bronchospasm and chest infiltrates disappeared. During the process of OC tapering, a new relapse occurred, bronchospasm being the most relevant clinical symptom that forced us to increase again the dose of OC. A skin prick test was performed that was positive for mite dust. Total blood IgE level was 253 IU/mL. Omalizumab treatment was started at the dose calculated according to the patient's weight and IgE concentration. The patient progressively improved and

More recently, Noga et al⁴ demonstrated an increase in eosinophil apoptosis and a decrease in granulocyte-macrophage colony-stimulating factor. All this information can help to explain the benefits of omalizumab in CEP.

In their report, Kaya et al¹ communicate that their patient remains free of symptoms 15 months after omalizumab treatment began, but they do not state future treatment options. We believe some of these patients can benefit from a decreasing dose protocol.²

*Christian Domingo, MD
Xavier Pomares, MD
Barcelona, Spain*

Affiliations: From the S. de Pneumologia, Corporació Parc Taulí, Departament de Medicina, Universitat Autònoma de Barcelona.

Funding/Support: The authors' research was partially supported by Beca Fucap 2008.

Financial/nonfinancial disclosures: The authors have reported to *CHEST* that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Correspondence to: Christian Domingo, MD, S. de Pneumologia, Corporació Parc Taulí, Parc Taulí 1, 08280 Sabadell, Barcelona, Spain; e-mail: cdomingo@tauli.cat

©2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.

DOI: 10.1378/chest.12-2035

TRACTAMENTS ANTI-IgE

Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice


Hans D. Brightbill,¹ Surinder Jeet,¹ Zhonghua Lin,¹ Donghong Yan,¹ Meijuan Zhou,¹ Martha Tan,² Allen Nguyen,² Sherry Yeh,² Donnie Delarosa,² Steven R. Leong,¹ Terence Wong,³ Yvonne Chen,³ Mark Ultsch,⁴ Elizabeth Luis,⁵ Sree Ranjani Ramani,⁵ Janet Jackman,¹ Lino Gonzalez,⁵ Mark S. Dennis,³ Anan Chuntharapai,³ Laura DeForge,² Y. Gloria Meng,² Min Xu,¹ Charles Eigenbrot,⁴ Wyne P. Lee,¹ Canio J. Refino,¹ Mercedesz Balazs,¹ and Lawren C. Wu¹

¹Department of Immunology, ²Department of Assay and Automation Technology, ³Department of Antibody Engineering, ⁴Department of Protein Engineering, and ⁵Department of Protein Chemistry, Genentech Inc., South San Francisco, California, USA.

The Journal of Clinical Investigation <http://www.jci.org> Volume 120 Number 6 June 2010

QUILIZUMAB


- Ac humanitzat
- S'uneix al segment M' de la IgE expressada per la Cél·lula B
- Afavoreix l'apoptosi de les Cèl·lules B diferenciades (expressen IgE de membrana)
- Disminueixen les IgE plasmàtiques en disminuir la seva producció.



TRACTAMENTS ANTI-IgE

QUILIZUMAB

B cell




TRACTAMENTS ANTI-IgE

LUMILIXIMAB


FcεRII receptor (CD23)

(RECEPTOR DE BAIXA AFINITAT)



Cèl·lula B

TRACTAMENTS ANTI-IgE



ALTRES TRACTAMENTS (I)

TRACTAMENTS ANTI-IL5

- MEPOLIZUMAB
- RESLIZUMAB

TRACTAMENTS ANTI-RECEPTORS DE L'IL5

- BENRALIZUMAB

TRACTAMENTS ANTI-IL-5. MEPOLIZUMAB

Autor	Corticoides	Efecte
Lecki (2000)	No	↓ Eosinòfils en sang
Flood-Page (2003)	No	↓ 100% Eosinòfils en sang, 52% medul·la i 54% a via aèria
Menzies-Gow 2003	No	↓ Eosinòfils a medul·la i mucosa bronquial
Flood-Page (2007)	Si	↓ Eosinòfils en sang i esput Absència de millora en exacerbacions, FEV1 o medicació de rescat

HIPÒTESIS:

- ☐ Eosinòfils de la via aèria tenen menys receptors de membrana per l'IL5
- ☐ Persistència d'eosinòfils a la via aèria
- ☐ Els malalts van ser escollits en funció del fenotip i no de l'endotip


TRACTAMENTS ANTI-IL-5. MEPOLIZUMAB

Autor	Corticoides	Efecte
Nair (2009)	Si	↓ Eosinòfils en sang i esput ↓ N° d'exacerbacions i temps d'aparició Efecte estalviador de corticoides Milloria significativa del FEV1 Milloria en qualitat de vida
Haldar (2009)	Si	↓ Eosinòfils en sang i esput ↓ N° d'exacerbacions i temps d'aparició Absència d'efecte estalviador de corticoides Absència de milloria del FEV1 Milloria en qualitat de vida

HIPÒTESI:

Mepolizumab podria ser eficaç solament en malalts amb:

- Asma refractària
- Asma amb perfil eosinofílic




TRACTAMENTS ANTI-IL-5. RESLIZUMAB


Autor	Corticoides	Efecte
Kips 2003	Si (inh. + orals)	↓ Eosinòfils en sang Milloria significativa del FEV1 Absència de milloria en qualitat de vida
Castro 2011	Si	↓ Eosinòfils en sang i esput Milloria significativa del FEV1 No ↓ Exacerbacions Absència de milloria en qualitat de vida

TRACTAMENTS ANTI-RECEPTORS DE IL-5. **BENRALIZUMAB**

EFFECTES:

- Neutralitza l'efecte de l'IL-5
- Afavoreix l'apoptosi





MEPOLIZUMAB
RESLIZUMAB

BENRALIZUMAB

ALTRES TRACTAMENTS (II)


TRACTAMENTS ANTI-IL-13

- LEBRIKIZUMAB


TRACTAMENTS ANTI- IL-4 + IL-13

– DUPILUMAB

TRACTAMENTS ANTI-IL-13.




IL-13




TRACTAMENTS ANTI-IL-13: LEBRIKIZUMAB


A Total Cohort



B High-Periostin Subgroup




C Low-Periostin Subgroup





Ac monoclonal humanitzat tipus IgG4
Marcadors de resposta: FENO i Periostina

TRACTAMENTS ANTI-IL-4 + IL-13: DUPILUMAB



IL-4



IL-13

TRACTAMENTS ANTI-IL-4 + IL-13

PITRAKINRA: es una variant de la IL-4 humana que es comporta com un inhibidor competitiu del receptor IL-4alfa (IL-4Ra) de manera que interfereix en l'acció tan de l'IL-4 com de l'IL-13.

